Trials / Terminated
TerminatedNCT03936933
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Two Arm, Multicentric, Randomized, Open Label, Parallel, Multiple Dose Study Subcutaneous Injection of Goserelin 3.6 Mg (Eurofarma) Vs ZOLADEX 3.6 Mg (AstraZeneca) Administered Subcutaneously in Premenopausal Patients with Breast Cancer.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eurofarma Laboratorios S.A. · Industry
- Sex
- Female
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Not accepted
Summary
A two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic study in premenopausal patients with advanced breast cancer.
Detailed description
A phase III, two arm, multi centric, randomized, open label, parallel, multiple dose pharmacodynamic study in premenopausal patients with breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Goserelin acetate 3.6 mg Injection | 3.6 mg, Subcutaneously at every 28 days |
| DRUG | ZOLADEX® 3.6mg Injection | 3.6 mg, Subcutaneously at every 28 days |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2024-09-30
- Completion
- 2025-01-30
- First posted
- 2019-05-03
- Last updated
- 2025-02-17
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT03936933. Inclusion in this directory is not an endorsement.